(Q52337223)

English

The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.

scientific article published in July 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. (English)

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

0 references

1 reference

based on heuristic

inferred from title

author name string

Despotis GJ

1

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Joist JH

2

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Hogue CW Jr

3

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Alsoufiev A

4

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Kater K

5

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Goodnough LT

6

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Santoro SA

7

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Spitznagel E

8

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Rosenblum M

9

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Lappas DG

10

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

language of work or name

0 references

publication date

1 July 1995

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

The Journal of Thoracic and Cardiovascular Surgery

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

110

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

1

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

46-54

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Monitoring heparin anticoagulation and its neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Comparison study of the Hepcon System Four and the Hemostasis Management System

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Development and evaluation of a disposable device for performing simultaneous duplicate bleeding time determinations

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

A Simple Method of Heparin Management During Prolonged Extracorporeal Circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Adequate Anticoagulation During Cardiopulmonary Bypass Determined by Activated Clotting Time and the Appearance of Fibrin Monomer

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Heparin monitoring and neutralization during cardiopulmonary bypass using a rapid plasma separator and a fluorometric assay

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Effect of Heparin and Heparin Fractions on Platelet Aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Inhibition of factor VIII-associated platelet aggregation by heparin and dextran sulfate, and its mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0022-5223%2805%2980008-X

7 January 2021

Identifiers

10.1016/S0022-5223(05)80008-X

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

1 reference

Europe PubMed Central

29 April 2018

http://europepmc.org/abstract/MED/7609568

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52337223&oldid=1584906113"